Section 1. EPR-3 versus GINA 2008 Guidelines – Asthma Control and Step 3 Care by Jean Bousquet & William W. Busse
CONFERENCE PROCEEDINGS
Section 1. EPR-3 versus GINA 2008 Guidelines – Asthma
Control and Step 3 Care
Highlights of the Asthma Summit 2009: Beyond the Guidelines
Jean Bousquet, MD,1 and William W. Busse, MD2
Abstract: Recent updates to asthma guidelines from the Global Ini-
tiative for Asthma (GINA) and the National Asthma Education and
Prevention Program (Expert Panel Report 3, EPR-3) share many sim-
ilarities, reflecting a focus on asthma control based on clinical mani-
festations of disease and responsiveness to therapy. Both documents
build upon the recommendations of former guidelines utilizing evi-
dence-based review of the published literature to revise algorithms for
practice. A major difference between the 2 reports is the preferred
treatment at Step 3. The GINA guidelines recommend a combination of
low-dose inhaled corticosteroid (ICS) plus long-acting -agonist
(LABA), whereas the EPR-3 advises either monotherapy with medium-
dose ICS or the low-dose ICS LABA combination. Both approaches
are supported by clinical experience and Level A evidence. The option
of personalized therapy is a point of discussion for future guidelines.
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INTRODUCTION
The evolution of the Global Initiative for Asthma (GINA)guidelines reflects a shift in the paradigm for asthma treat-
ment.1 The 1995 and 2002 versions of the guidelines proposed
that treatment decisions be based on disease severity.2,3 The
1995 guidelines classified disease severity into one of 4 catego-
ries based on the frequency of symptoms, exacerbations, noc-
turnal symptoms, forced expiratory volume in the first second
(FEV1), or peak expiratory flow (PEF) before treatment began.2
However, many patients were already on treatment when phy-
sicians first saw them, making classification of disease severity
difficult. Later discussion suggested accounting for these pa-
tients by classifying disease severity and recommending treat-
ment based on clinical features and step of medication regimen.3
However, this scheme was complex and presented a consider-
able challenge to primary care physicians, who are often the
main providers for patients with asthma.
Data suggesting that poorly controlled asthma days
were more important in treatment considerations4 played an
important role in providing the 2002 updated guidelines with
a focus on asthma control.3 The difficulty with this approach
is that the definition of asthma control can differ based on the
assessment used, and who is assessing control. For example,
“control” may mean different things to the patient, the care-
giver, the general practitioner, the respiratory physician, or to
the regulatory authority. Furthermore, current treatment ap-
proaches are guided by single clinical end points, which
might overestimate true asthma control. This was illustrated
by a study showing that the percentage of patients exhibiting
asthma control differed across single end points.5 A compos-
ite measure of control might help to improve outcomes.
The 2008 GINA guidelines define severity based on
clinical manifestations of the disease and how these manifesta-
tions respond to therapy (Table 1).1 However, in recognition that
asthma severity can change over time, the guidelines no longer
recommend classification of asthma severity for treatment deci-
sions. Instead, GINA 2008 classifies asthma by level of control
and uses a protocol of 5 treatment steps as shown in Figure 1; the
former severity-based classification is recommended only for
research purposes.1 In this manner the most recent GINA guide-
lines recommend that treatment decisions be made based on the
patient’s level of asthma control.
According to GINA 2008, the preferred treatment for Step
3 (ie, for patients with moderate, persistent asthma) is a combi-
nation of low-dose inhaled corticosteroids (ICS) and long-acting
-agonist (LABA) for adults and medium-dose ICS for chil-
dren.1 This is based on a rich body of data from randomized,
controlled trials. In particular, clinical experience has supported
the findings of the budenoside/formoterol (Symbicort) Mainte-
nance and Reliever Therapy (SMART) study, which showed
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that using an ICS/LABA combination can effectively reduce
exacerbations and improve overall asthma control.6 Because of
the evidence linking LABA use alone with increased risk for
asthma-related death, GINA 2008 emphasizes that LABA
should not be used regularly as monotherapy, and the document
no longer lists LABA alone as an option for add-on therapy at
any step.1 Optional treatments for step 3, including increasing
the dose of ICS (particularly, in children) or using a combination
of ICS with leukotriene receptor antagonist or theophylline.
Having options such as these enhances the flexibility of treat-
ment to better meet patient needs.
There are more similarities to GINA 2008 and guidelines
from the National Asthma Education and Prevention Program
Expert Panel Report 3 (EPR-3) than differences.1,7 Both define
asthma control based on clinical manifestations and their respon-
siveness to therapy; both use similar language with respect to
exacerbations; and both propose similar steps in asthma man-
agement, including the partnership between patient and physi-
cian. The differences that exist are slight: for example, GINA
2008 includes response to therapy in assessments of asthma
control, whereas EPR-3 addresses resistance to treatment and
effect of comorbid conditions. In addition, the EPR-3 assess-
ment of asthma control is divided into domains of impairment
and risk, which are described more fully in Dr. Busse’s article
after this. The impairment domain is very similar to the GINA
control categories shown in Table 1.
In summary, many of the differences between the most
recent GINA and EPR-3 guidelines are semantic in nature.
These guidelines are excellent resources for specialists, but
probably not yet appropriate for the majority of general
practitioners who daily treat patients with asthma. We need to
now give consideration to developing a single, simplified, and
truly global guideline for those practitioners who see most of
the asthma patients worldwide.
A CHOICE AT STEP 3: THE NAEPP EPR-3
GUIDELINES
The National Heart, Lung, and Blood Institute
(NHLBI) of the National Institutes of Health released in 2007
FIGURE 1. GINA stepwise ap-
proach for managing asthma in
patients 5 years of age with
persistent mild or moderate dis-
ease, focus on step 3.1
TABLE 1. 2008 GINA Guidelines Emphasize Asthma Control1
Characteristic Controlled Partially Controlled Uncontrolled
Daytime symptoms None (twice or less per week) More than twice per week Three or more features of
partially controlled
asthma in any week
Limitations of activities None Any
Nocturnal symptoms None Any
Need for reliever rescue
medication
None (twice or less per week) More than twice per week
Lung function
(FEV1 or PEFR)
Normal or near-normal Less than 80% predicted or
personal best
Exacerbations None One or more per year, although any
exacerbation should prompt review
of maintenance treatment to ensure
it is adequate
One in any week
Treatment Maintain treatment and find
lowest controlling step
Consider stepping up to gain
control, and treat exacerbations
Step up treatment until
disease is controlled, and
treat exacerbations
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an update of the U.S. asthma clinical practice guidelines,
EPR-3: Guidelines for the Diagnosis and Management of
Asthma. This 400 page document incorporates an evi-
dence-based assessment of former guidelines and current
literature in revising the recommendations for practice.7 The
complete guidelines are available at www.nhlbi.nih.gov/
guidelines/asthma/asthgdln.htm.
The major difference between the 2007 EPR-3 and
earlier versions of the US guidelines is a focus on asthma
control, which is defined as the degree to which manifesta-
tions of asthma (ie, symptoms, functional impairments, risk
of untoward events) are minimized and the goals of therapy
are met.7 Asthma control is differentiated from asthma sever-
ity, which is defined as the intrinsic intensity of the disease
process, and which is most accurately determined before a
patient is placed on long-term therapy.7 Classifying asthma
severity is done to initiate treatment; assessing asthma control
is done for ongoing monitoring; and both are broken down to
domains of impairment and risk to operationalize therapeutic
targets as described in Table 2. The therapeutic targets are
defined by a step paradigm (Fig. 2), and when asthma is well
controlled at any level, improvements are observed in both
domains.7
For the most part, differences between the EPR3 and
the 2008 GINA guidelines are indeed a matter of semantics.
However, as shown in Figures 1 and 2, the 2 guidelines differ
in what they recommend as preferred treatment at Step 3.1
The GINA guidelines recommend a combination of low-dose
inhaled corticosteroid (ICS) and long-acting -agonist
(LABA) as the preferred treatment,1 whereas the EPR-3
recommends a more flexible approach that includes the op-
tion of either combination therapy or increasing the dose of
ICS.1 This is a greater degree of flexibility than earlier US
guidelines, and it is based on Level A Evidence.7–10
This change in the US guidelines has not been without
controversy. LABAs have been shown to improve lung func-
tion, decrease asthma symptoms and exacerbations, and
lower the ICS dose needed for control. However, the SMART
reported an increased risk of asthma-related mortality,11 and
higher doses of formoterol have been associated with an
increased likelihood of severe asthma exacerbations.12 Thus,
all agents that include a LABA must carry a Black Box
warning in the US; and the EPR-3 recommends that potential
FIGURE 2. EPR-3 stepwise ap-
proach for managing asthma in
patients 5 years of age with
persistent mild or moderate dis-
ease, focus on step 3 (adapted
charts for children 5–11 years of
age and youths 12 years of
age and adults).7
TABLE 2. Criteria for Targeting the Domains of Asthma




Reducing impairment ● Prevent chronic and troublesome symptoms
(eg, coughing or breathlessness in the daytime,
nighttime, after exertion)
● Infrequent use (£2 days/week) of inhaled
short-acting bronchodilator for quick relief
of symptoms
● Maintain (near) “normal” pulmonary function
● Maintain normal activity levels (including
exercise, other physical activity, attendance
at work or school)
● Meet patients’ and families’ expectations of and
satisfaction with asthma care
Reducing risk ● Prevent recurrent exacerbations of asthma;
minimize emergency department visits,
urgent care visits, hospitalizations
● Prevent progressive loss of lung function (for
children, prevent reduced lung growth)
● Provide optimal pharmacotherapy with minimal
(ideally, no) adverse effects
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benefits of using LABAs daily be balanced against the sug-
gested risks.7
It should be noted that these serious adverse events
were reported in patients who largely used LABAs alone.11,12
Furthermore, SMART was conducted in patients with severe
disease.11 Results from recent studies have found no in-
creased risk for death when LABA are used in combination
with ICS.13 In fact, the number of asthma-related deaths have
decreased with the advent of ICS/LABA combinations.
Several studies have suggested that adding a LABA is
more effective than increasing ICS dose for improving im-
pairment.14,15 For example, in the Gaining Optimal Control of
Asthma (GOAL) study, among patients with more severe
asthma, the percentage of those achieving control was higher
for patients taking a fluticasone propionate/salmeterol com-
bination than for those taking fluticasone alone.8 Likewise, in
the Formoterol and Corticosteroids Establishing Therapy
(FACET) study, a combination of low-dose budesonide and
formoterol appeared to be more effective than using budes-
onide alone.16
The distinction in terms of clinical benefit between
increasing the ICS dose and using an ICS/LABA combination
at Step 3 is not always clear cut. For example, in the GOAL
study, the percentage of patients with less severe disease
achieving well-controlled asthma was similar between those
using an increased dose of fluticasone alone and those given
the fluticasone/salmeterol combination.8 In the FACET study,
patients using increased doses of budesonide monotherapy
had fewer severe exacerbations than patients using the budes-
onide/formoterol combination.16 However, another study
showed that the budesonide/formoterol combination delayed
severe exacerbations when it was used both as maintenance
and reliever therapy, in contrast to either increasing the dose
of budesonide monotherapy or using the combination as
maintenance with a short-acting -agonist (SABA) as reliever.17 In
this study the number of severe exacerbations was compara-
ble for the increased ICS and ICS/LABA  SABA treat-
ments.
In a recent Canadian registry study the proportion of
patients receiving successful treatment (defined as no hospi-
talizations, no use of oral corticosteroids, and use of less than
1 dose per day of SABA) was compared with the effective-
ness of either increasing the current dose of ICS or adding a
LABA.18 Both approaches were similar when the compara-
tive outcome was symptoms, that is, impairment. In contrast,
when the need for frequency of oral prednisone courses was
evaluated, those who received an increase in ICS had a
reduced need for prednisone bursts. An accompanying edito-
rial suggested that increasing the ICS dose permits better
control of inflammation, making the airways less susceptible
to exacerbation, whereas adding a LABA most likely reduces
measures of impairment.19 This raised the question that the
addition of a LABA reduced symptoms but not underlying
inflammation. With the additional ICS, there was a reduction
in airway inflammation and with this effect, fewer exacerba-
tions. In addition, we should consider whether there is a
group of patients for whom combination therapy does not
work, or for whom monotherapy works better. Biomarkers
are needed to identify those patients. Sputum eosinophils
might be useful in signaling propensity for exacerbation, but
their use as a marker is still limited.20 Patient preferences also
must be considered. Interestingly, most patients are not con-
cerned so much with exacerbations as they are with risks for
side effects. Thus, the debate about increased ICS dose versus
combination therapy with a LABA is likely to continue for
some time.
Several questions remain with respect to comparisons
between the EPR-3 and GINA guidelines. For example, the
best approach for stepping down treatment is not clear; both
guidelines address this issue, but data are limited.1,7 In addi-
tion, more study is needed in children. Most of the data
supporting increased ICS dosage or addition of a LABA
come from adult studies. As stated in the EPR-3 guidelines,
there are not enough data to substantiate a benefit for LABA
use in children younger than 11 years.7 In addition, it is not
clear how best to approach exacerbations that show no
eosinophil infiltration and are, thus, unresponsive to cortico-
steroids. The mechanism underlying these exacerbations is
not clear, and it could be that different triggers dictate
different pathways to exacerbations.
SECTION 1 DISCUSSION
Dr. Bousquet: I have a few comments. I think the
concept of impairment and risk is very good and may provide
a better approach to treatment. Guidelines are evolving.
However, I believe that there should be a common guideline,
a common approach. In fact, the various guidelines are not
very different. Also, in terms of treatment what is important
in today’s guidelines are combination therapy with an ICS
and LABA in a single inhaler and also using ICS and then
doubling the dose when there is an exacerbation.
Dr. Busse: I would agree.
Dr. Bousquet: The guidelines are moving us toward a
flexible approach to therapy, even in the States. My usual
treatment is the SMART approach, that is to say flexible
therapy. Clearly, it reduces impairment; the number of seri-
ous exacerbations goes down. I don’t know if it substantially
reduces risk. The problem is to me compliance. Most of the
patients I see with severe asthma are patients who do not take
their treatment.
Dr. Busse: I think what we’d like to have is some
marker we could use to find out who’s at risk. At this time
there are a limited number of options. Exhaled nitric oxide
certainly is a marker of airway inflammation and may be
helpful in knowing when to reduce ICS, but it may not
necessarily tell us when we have to up-regulate the dose.
Sputum eosinophils mark a propensity toward an exacerba-
tion, but most places have limitations in being able to do this.
Dr. Oppenheimer: Patient preference should be a factor
when assessing risk. Apparently, some patients are not as
concerned about the risk of an exacerbation as they are about
the risk of sudden death with LABA or about side effects of
ICS; and they make their decision on what they’ll comply
with often on those aspects.
Dr. Bousquet: Frankly speaking, this is more of a US
concern. However, steroid phobia is a major concern in
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France, which is why I use more combination therapy than
ICS monotherapy.
Dr. Busse: I think the concerns about LABAs are more
of a scare than reality. But, how you can quell your patients
when they hear this in the news?
Dr. Storms: I have a question about the risk domain. Let
me use a case scenario. A patient comes in on combination
therapy in June and gives a history of having had 2 pred-
nisone bursts in the winter due to URIs. The rest of the year
her asthma is totally controlled. Pulmonary function is 85%
predicted FEV1. Based on the risk domain, what would you
tell her?
Dr. Busse: That’s a good question. Based on the GOAL
data, the exacerbations should decrease by either increasing
the dose of ICS or ICSLABA in combination. But, more
importantly, the longer you use the higher doses of either
approach, the lower the rate goes. For some patients who are
“exacerbation prone,” increasing the dose and maintaining
the increase over a longer period of time might protect them
from an exacerbation to some degree. It’s not perfect, though.
Dr. Storms: So you would increase the dose all year?
Dr. Busse: Yes, absolutely.
Dr. Bousquet: I might do something else. I would
increase the dose of combination therapy as the patient has
a cold.
Dr. Gelfand: It seems to me that the triggers of the
exacerbation dictate the pathways that are activated and,
ultimately, the therapeutic arms that are going to be effective.
Many exacerbations, depending on the trigger, have no eo-
sinophils and are unresponsive to corticosteroids.
Dr. Bousquet: I cannot agree more; but the data con-
sistently have shown that if you increase the dose of combi-
nation therapy early on in the exacerbation, you reduce the
risk of exacerbation and subsequent exacerbations.
Dr. Busse: I agree that the mechanism by which these
people exacerbate is important, and until we understand the
mechanism, we don’t know what we’re going after. I think
it’s an unmet need.
Dr. Hargreave: We’ve heard about stepping up to bring
about control, but not about then stepping down. And this can
have different consequences. For example, in stepping up
control, as we’ve heard, you might use combination therapy.
But, once control is achieved, combination therapy may no
longer be needed, or the dose of ICS might need to be
reduced. Can you comment on that?
Dr. Bousquet: Well, in the GINA guidelines, there are
only B and D evidence for stepping down.
Dr. Busse: The EPR-3 didn’t address it either due to the
lack of data. A marker of inflammation would be helpful,
because right now it’s arbitrary—if you’re stable for 3
months, consider a reduction; yet, 3 months may not be
sufficient time to stabilize. It’s an area that hasn’t been
addressed very well.
Dr. Bukstein: Most of the people instituting guidelines
today are primary care physicians (PCPs), and they have
multiple guidelines. One of the things that most of their
guidelines stress, which PCPs are used to, is patient lifestyle.
We haven’t talked about lifestyle change.
Dr. Spector: That is a good point. In the real world
people have their own ideas, and there can be some big
differences ethnically. We just completed a survey of patients
and PCPs about guidelines and controller medications.
More than 25% of the patients and 14% of the physicians
stated that they would stop the medication when asymp-
tomatic. The percentages are greater in Blacks and in
Hispanics who have different concepts of care and, maybe,
different access to care.
Dr. Busse: Let me comment a little further. In an
asthma control evaluation conducted in inner cities in the US
in a high-risk group of patients, we looked at whether care
would improve if a biomarker, in this case exhaled nitric
oxide (eNO), was added to a guideline-based algorithm for
treatment. Under those circumstances, the additional marker
of inflammation wasn’t very helpful. During the study adher-
ence with care was high, but when the study ended, many
patients went back to previous ways of managing their
disease. They didn’t have medication available. So, it’s not
just the guidelines. It’s having a way of implementing and
applying them that make the difference. Some of this may
be social and some of it may be economic, but both are
important.
Dr. Brightling: Related to this, the observation that
almost without exception patients get better in clinical trials
has actually been the undoing of a lot of studies because it
obviously impacts on the exacerbation frequency during the
study. Clearly, it’s partly due to improvements in care, access
to care, and access to treatment; but it’s also related to how
patients adapt to actually tolerate their poor disease control.
For example, I saw a patient who is in his 30s in our difficult
asthma clinic He usually cycles to work, but told me that he
had stopped for the last 6 months due to poor asthma control.
Instead of increasing his therapy, he tolerated the fact that he
could not cycle and had to drive. Many patients dislike their
therapy; and they actually adapt their lifestyles around being
able to tolerate poor control.
Dr. Oppenheimer: I would agree. I think there are 2
domains of impediment. The first is the doctor, and the
second is the patient. The asthma guideline is estimated to
have been read by about 75% of PCPs, but the busiest
clinicians tended to use it the least. Yet, these are the very
people who we are writing these guidelines for; they take care
of the majority of asthmatics. We keep talking about spirom-
etry being a useful tool and the fact that there’s no one
measure of control. Are PCPs really going to adhere to the
guidelines if they are not doing spirometry, and how much
are we really missing?
Dr. Bukstein: It’s not just physicians and patients; it’s
also the regulatory bodies. One of the problems with guide-
lines is that they are used by people who regulate how we
practice, converting them into a step care plan that fits their
paradigm of decreasing costs.
As far as lung function testing, even if we could get
PCPs to do lung function testing, I doubt that it would result
in a lot of change. I think what is more important is an
emphasis on unifying the risk benefit analysis for the physi-
cian and the patient, bringing them closer together, under-
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standing the burden of disease and the burden of therapy to
assess potential benefit.
Dr. Brightling: In the UK the uptake for spirometry by
PCPs has increased enormously over the last 2 years because
they are now funded to do regular spirometry on patients with
chronic lung disease. This is ironic. As Dr. Bousquet pointed
out an important difference between the EPR-3 and GINA
guidelines is the value of doing repeated measures of spirom-
etry within a primary care population. It has value in terms of
trying to establish a diagnosis, but in the EPR-3 guidelines
spirometry also has a major role in terms of looking at risk.
I would challenge that view and suggest that it may be
overstated. The level of spirometry may not be as closely
related to risk of exacerbations as we think. Other control
measures, such as the ACQ 6 may be more valuable. Clearly,
if you look at the difficult asthmatics, there is a population of
patients who have unstable disease and frequent exacerba-
tions, but normal spirometry between episodes.
Dr. Bousquet: Spirometry in GP offices may not be
very reliable; it’s not so easy to do, it’s more complicated
than doing blood pressure.
Dr. Busse: I think that spirometry is a measure by which
you can look at one end point, but there’s variability. However,
as Dr. Bousquet indicated, many times people don’t perceive
their fall in lung function because it’s so gradual. They can be
living at 60% and accept it, and they adjust their lifestyle rather
than do anything. It underscores the fact that asthma in many
cases is a very complex disease, which requires sophistication in
terms of evaluation and understanding of the disease.
Dr. Bukstein: But shouldn’t the guidelines take a more
practical approach? Maybe there should be separate guide-
lines for PCPs taking into account what they can and cannot
do on a practical basis. Also, should guidelines address things
outside of pharmacologic therapy in a more aggressive man-
ner, things like how drugs are paid for and the importance of
access to medication, to treatment? Again, one of the most
common reasons that exacerbations occur is poor access to
medications.
Dr. Bousquet: One problem is that guidelines are usu-
ally written by the most sophisticated doctors who see the
most severe patients. Patients and GPs are not included. This
needs to be fixed because if you write guidelines which are
not applicable in primary care, they will not be used. Also, if
you write guidelines that are not agreeable to patients, they
will not be used.
Another issue is to keep things simple. The concept of
risk and benefit makes things more complex. So, is this an
approach for the specialist or is it an approach for the GP?
Dr. Busse: We need to recognize that many patients do
read the guidelines, and they emerge with an understanding
of what expectation should be as far as their disease control.
The NAEPP did point out times when it is important to see
the consultant, particularly for patients with frequent exacer-
bations. Cost of medications is political, but patient expecta-
tions for disease control may be very helpful.
Dr. Oppenheimer: What about alternative dosing?
Dr. Busse: To some extent this is FDA driven. But, I
agree that we need to start to make adaptations to the
phenotype of the patient. Some patients can do very well on
episodic treatment; others might do well on other forms of
treatment. We need to be innovative, not rigid. The guidelines
are a framework, not rules.
Dr. Spector: Some patients cannot afford ICS or
combination therapy. Do we need to have other guidelines
for patients who can’t afford the medication that we’re
advocating?
Dr. Bousquet: As many as 50% of the world population
cannot get access to ICS; yet, this is the critical drug. ICS can
reduce most of the severity of asthma and most of the
exacerbations. So, we need to make available generic, low-
cost, ICS of high quality.
Dr. Oppenheimer: There’s a lot of interesting data
coming out on anxiety and depression having significant
impact on patient perception about disease control. Is that a
domain that we’re not addressing aggressively enough?
Dr. Bukstein: Depression, and all the other parts of
lifestyle, is incredibly important.
Patients need to have better self efficacy if we’re going
to help them control their disease, and one thing that helps
with self efficacy is the idea that the individual can modify his
or her therapy, that they are empowered. Flexibility, however
it is built it into a patient’s therapy, is going to be very
helpful.
Dr. Busse: An interesting study in a mouse model
showed that a chronic increase in anxiety was associated with
steroid insensitivity. It makes you wonder about the brain
connection. The depressive index in asthma is extremely
high. How that integrates with responsiveness to therapy may
be important.
Dr. Calhoun: So, how can we put some of this into
action? Could we have our medical societies work with
vendors of electronic medical records (EMR) to implement
guidelines? The EMR is clearly the wave of the future.
Dr. Bukstein: I think that’s key. System change will
yield the biggest benefit, but I think it would take a real push
between all the organizations to do that. The only way we’re
going to get PCPs to really institute guidelines is to model
that with some sort of interactive information. As the guide-
lines evolve, some thought has to be given as to how the
information is going to be transmitted to primary care.
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